Trademark Overview
On Friday, August 23, 2024, a trademark application was filed for CPTX with the United States Patent and Trademark Office. The USPTO has given the CPTX trademark a serial number of 98714397. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, May 23, 2025. This trademark is owned by CPTx GmbH. The CPTX trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations, namely, DNA, synthetic DNA and single-strand DNA for use in the fields of gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, antivirals, and synthetic DNA nanostructures in general; medicines comprised of DNA for gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, antivirals, and synthetic DNA nanostructures in general; nucleotide sequences for medical and veterinary purposes
Medical and pharmaceutical services in the field of DNA, namely, DNA analysis services for medical purposes, DNA screening for medical purposes, genetic testing for medical purposes.
Scientific and technological services, namely scientific research and analysis in the field of DNA; biochemical and biotechnological services, namely research and development of custom-specific DNA; research services in the field of DNA; biochemical and biotechnological services, namely protein design and development; testing of new products for third parties; scientific DNA screening for scientific research purposes for third parties; protein screening for scientific research purposes for third parties; industrial DNA screening for third parties for the purposes of scientific and biotechnological research and development; industrial protein screening for third parties for the purposes of scientific and biotechnological research and development.